Ansuman T. Satpathy, M.D., Ph.D., Technology Impact Award RecipientStanford University

This grant has been instrumental in allowing my laboratory to pursue high-risk high-impact ideas, which would not have been possible without CRI’s funding and collaborative scientific network.
Area of Research: All Cancers

Checkpoint immunotherapies targeting the PD-1 pathway can enhance the ability of T cells to destroy tumors and have been effective in a variety of human cancers. However, these therapies are not effective in all patients with a given cancer subtype, nor in all cancers, and therefore studies interrogating the molecular basis for successful immunotherapy response are needed. To that end, Dr. Satpathy is employing novel single-cell sequencing technologies to identify the key gene regulatory mechanisms that underlie immunotherapy resistance in patients with basal cell carcinoma, which has a 30% response rate.

Additionally, he’s developing other single-cell methods to characterize the T cell receptor repertoires and epigenomes of “killer” T cells as well as using CRISPR genome editing tools to engineer T cells with enhanced capabilities against cancer. Overall, Dr. Satpathy anticipates that his findings will provde novel insights into the regulation of effective anti-tumor responses in patients and uncover new strategies for immunotherapeutic intervention.

Projects and Grants

Single-Cell Epigenome Technologies for Cancer Immunotherapy

Stanford University | All Cancers | 2020

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.